Actively Recruiting
Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population
Led by LMU Klinikum · Updated on 2024-10-09
180
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate potential differences in procedural outcomes of both commercially available transcatheter edge-to-edge mitral valve repair devices in a non-selected clinical setting.
CONDITIONS
Official Title
Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age equal or above 18 years
- Written consent
- Heart Team recommends M-TEER
You will not qualify if you...
- Mitral Stenosis (MV mean PG > 5 mmHg)
- Cardiogenic shock or hemodynamic instability at the time of intervention
- Active endocarditis
- Participant in another interventional cardiology study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
LMU Klinikum
Munich, Bavaria, Germany, 81377
Actively Recruiting
Research Team
J
Jörg Hausleiter, Prof. Dr.
CONTACT
L
Ludwig Weckbach, PD Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here